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Summary Forty-one human tumour cell lines were examined for the production of epidermal growth factor
(EGF)/transforming growth factor (TGF)-oa-like activity (EGF/TGF-a-LA), immunoreactive (IR-) EGF and
IR-TGF-a. EGF/TGF-a-LA was determined by radioreceptor assay, in which the factors with capacity to
bind to EGF receptor could be detected. IR-EGF and IR-TGF-oe were determined by the respective
radioimmunoassays. Both EGF/TGF-a-LA and IR-TGF-a were detected in 11 tumour cell lines. The levels of
EGF/TGF-oc-LA correlated well with those of IR-TGF-a. A small amount of IR-TGF-cx was detected in five
other lines. In contrast, IR-EGF was not detectable in any of the 41. Consequently, it can be concluded that
EGF/TGF-a-LA produced by human tumour cells is mainly TGF-cc rather than EGF. It was also revealed
that melanoma cell lines produce a large amount of TGF-a frequently. Gel filtration studies revealed that
TGF-a produced by melanoma cell lines was identical to human (h) TGF-a(I-50), except for one line, in
which IR-TGF-a with a different molecular size was detected. Northern blot analysis revealed that bands
corresponding to hTGF-a mRNA were present in melanoma cell lines producing a large amount of
IR-TGF-a, indicating that the TGF-c produced is the product of hTGF-a gene. Further studies are required
to discover the actual biological roles of TGF-a produced by melanoma cells as well as other types of cancer
cells.
Recent progress in growth factor research has revealed that
cancer cells produce epidermal growth factor (EGF)/
transforming growth factor (TGF)-a-like biological activity.
The activity produced by several tumour cell lines has been
characterised and is considered to be TGF-oa (Marquardt et
al., 1983; Perroteau et al., 1986; Derynck et al., 1987; Smith
et al., 1987). Also, the expression of TGF-oa mRNA in
several tumour cell lines has been revealed (Derynck et al.,
1987). However, it has been reported that some gastric
cancer cell lines produce EGF (Mori et al., 1987) and some
breast cancer cell lines express EGF mRNA (Murphy et al.,
1988). With the aim of clarifying whether the major factor
with EGF/TGF-oc-like biological activity produced by human
tumour cells is TGF-a or EGF, we have examined tumour
cell lines for production of TGF-a and EGF by using the
respective radioimmunoassay (RIA) as well as the radio-
receptor assay (RRA). In the RRA, EGF/TGF-a-like
activity (EGF/TGF-a-LA), representing factors with capacity
to bind to EGF receptor, could be detected. Since the
present study demonstrated that melanoma cell lines produce
a large amount of TGF-a with high frequency, TGF-a
production by the melanoma cell lines was further analysed
by Northern blot hybridisation and gel filtration techniques.
Materials and methods
Human tumour cell lines
The 41 human tumour cell lines examined in this study were
from seven melanomas (SEKI, A-375, VMRC-MELG, G-
361, WM-115, WM-226-4 and Mewo), four lung adeno-
carcinomas (A-549, PC-7, PC-9 and PC-14), two lung
squamous cell carcinomas (VMRC-LCP and EBC-1), three
lung small cell carcinomas (Lu-130, Lu-134-A and Lu-135),
seven gastric carcinomas (KATO-III, MKN-7, MKN-28,
MKN-45, MKN-74, OKAJIMA and AZ-521), three hepato-
cellular carcinomas (Li-7, PLC/PRF/5 and HuH-7), three
mammary carcinomas (MCF-7, BT-20 and ZR-75-1), two
colonic carcinomas (KITAJIMA and HT-29), four
pancreatic carcinomas (MIAPaCa-2, ASPC-1, PANC-1 and
BxPC-3), three urinary bladder carcinomas (T-24, HT-1197
and HT-1376), an acute promyelocytic leukaemia (HL-60),
an acute lymphoblastic leukaemia (Molt-4) and an epitheloid
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carcinoma (Hela). SEKI (Fujita et al., 1980), Lu-130, Lu-
134-A, Lu-135 (Terasaki et al., 1986) and Li-7 (Beattie et al.,
1982) were established at the National Cancer Center
Research Institute (Tokyo, Japan). MKN-7 (Motoyama et
al., 1986) and KITAJIMA (Hitomi et al., 1986) were kindly
provided by Dr Hidenobu Watanabe (Niigata University,
Niigata, Japan). PC-7, PC-9 and PC-14 (Lee et al., 1985b)
were kindly provided by Dr Yoshihiro Hayata (Tokyo
Medical College, Tokyo, Japan). A-375, G-361, WM-115,
WM-266-4, A-549, KATO-I1I, MCF-7, BT-20, ZR-75-1,
HT-29, MIAPaCa-2, ASPC-1, PANC-1, BxPC-3, T-24, HT-
1197, HT-1376, HL-60, Molt-4 and Hela (American Type
Culture Collection, 1985) were purchased from the American
Type Culture Collection (Rockville, MD, USA). VMRC-
MELG, Mewo, VMRC-LCP, EBC-1, MKN-28, MKN-45,
MKN-74, OKAJIMA, AZ-521, PLC/PRF/5 and HuH-7
(Japanese Cancer Research Resources Bank, 1986) were
provided by the Japanese Cancer Research Resources Bank
(Tokyo, Japan). All of these cell lines were maintained at
37°C under 5% CO2 95% air in 75cm2 plastic tissue culture
flasks by using the original medium described in the
references and the catalogues. The culture media for all these
cell lines were supplemented with 10% fetal calf serum
(FCS). When the cells had grown to 90% confluence, the
spent media of these cell lines were collected and analysed.
Extraction method
The spent medium (10ml) was applied to an activated
octadecylsilylsilica (ODS) cartridge (Sep-pak C18, Waters,
Milford, MA, USA). The material retained on the ODS
cartridge was eluted with 3ml of 80% acetonitrile in 0.1%
trifluoroacetic acid. The eluates were lyophilised and
reconstituted to 1.0ml with assay buffer (Imanishi et al.,
1988). As control, the same volume of fresh medium (newly
prepared culture medium supplemented with 10% FCS) for
each human tumour cell line was extracted in the same
manner. Furthermore, to determine the recovery rate of the
extraction method, recombinant human (h) TGF-ax(1-50) and
hEGF(1-53) purchased from Earth Chemical (Akoh, Japan)
were added to fresh medium and extracted.
RRA and RIAs
The levels of factors with capacity to bind to EGF receptor,
EGF/TGF-a-LA, were determined by RRA, which was
carried out by using the membrane fraction prepared from a
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human epidermoid carcinoma cell line, A431, by the method
reported previously (Imanishi et al., 1988). Recombinant
hTGF-ac(I-50) was used as the assay standard and
recombinant hEGF radioiodinated by the chloramine-T
method (Hunter & Greenwood, 1962) was used as the
labelled antigen.
Human TGF-a RIA was performed by using an antiserum
against hTGF-a(1-7) as described previously (Imanishi et al.,
1988). Recombinant hTGF-cx(I-50) was used as the assay
standard and the labelled antigen.
Human EGF RIA was performed with a rabbit antiserum
(TRK-102) raised against highly purified hEGF from human
urine, which was provided by Earth Chemical. Recombinant
hEGF was used as the assay standard and labelled antigen.
To test whether this assay system could recognise
authentic hEGF, 10 urine specimens prepared from healthy
volunteers were assayed by the hEGF RIA.
The specificity of these assay systems was determined by
using recombinant hTGF-a(I-50), hTGF-a(1-7), hTGF-oc(33-
50) and recombinant hEGF. The results were expressed as
equivalents to nmol of the respective growth factors per litre
of spent media (nmol 1 -1).
Gel filtration studies of TGF-a in melanoma cell lines
Extracts prepared from the spent media of four melanoma
cell lines were chromatographed on a Sephadex G-50
superfine column (1.0 x 45cm) which was equilibrated and
eluted with I molI1- acetic acid. The column was calibrated
with hTGF-ax(I-50) and the samples were always
supplemented with 1251-human albumin and Na125I as
internal markers.
Northern blot analysis in melanoma cell lines
Northern blot hybridisation for hTGF-ac mRNA was also
performed with the seven melanoma cell lines by the method
described previously (Honda et al., 1988). For detecting
hTGF-a mRNA, a 60-base probe complementary to hTGF-
at(1-20) was used (Figure 1). Furthermore, in order to
compare the amount of poly(A)+ RNA prepared from each
cell line, the levels of human P-actin mRNA were determined
by the method described previously (Suzuki et al., 1987).
Densitometric analysis was performed with a computing
densitometer (Suzuki et al., 1987), and the amounts of
hTGF-a mRNA in the respective cells were estimated as the
ratio of hTGF-a mRNA to /3-actin mRNA.
Results
RRA and RIAs
The amounts of hTGF-a which inhibited the labelled antigen
binding by 10% and 50% were 30 and 900fmol per tube,
respectively, when determined by RRA, and hTGF-a RIA,
gave figures of 26 and 150fmol per tube, respectively. In the
case of hEGF RIA, the amounts of hEGF were 2.1 and
9.2fmol per tube, respectively. Cross-reactivities of hTGF-ax,
fragments and hEGF in these assay systems are summarised
in Table I. When the 10 urine samples from healthy
volunteers were analysed, they were found to contain
immunoreactive (IR) EGF ranging in concentrations from
3' 5'
Probe: cAc CAC AmG GTA Am TTA cTG ACG GGT CA AmG GTG TGA GC AAG AC MG GTA cc TMG
5' -3'
Figure 1 Structure of hTGF-a mRNA and synthetic probe. The
coding region and the untranslated region of the mRNA are
shown by the box and by the single line, respectively. The
hatched section ofthe box indicates the mature protein. The probe
(60 bases) can hybridise to the portion of hTGF-a mRNA cor-
responding to the amino-terminal 20 amino acids ofhTGF-a(l-50).
Table I Relative cross-reactivities of hTGF-a, its
fragments and hEGF in the three assay systems
Cross-reactivity (%)'
Peptide RRA hTGF-a RIA hEGF RIA
hTGF-a(l-50) 100 100 <0.01
(1-7) <2.0 180 <0.01
(33-50) <2.0 <0.08 <0.01
hEGF(I-53) 280 <0.08 100
aThe amounts of synthetic peptides that inhibited
the binding of the labelled antigens by 50% in the
respective RRA and RIAs were determined, and the
amount of hTGF-a(I-50) in RRA and hTGF-a RIA
and that of hEGF(I-53) in hEGF RIA were taken as
100%.
1.1 to 4.3nmoll-1 with dose-response curves parallel to that
of hEGF(1-53); these amounts were almost the same as those
reported previously by others (Uchihashi et al., 1982),
indicating that the hEGF RIA is useful for measuring
IR-EGF.
TGF-a-like activity in spent media
When 10ml of fresh medium containing 5.0 or 50pmol of
hTGF-a(1-50) were extracted, the recovery rates were
77.0+8.1% and 85.2+7.0% (mean+S.D.), respectively. In the
case of recombinant hEGF, they were 87.2+9.8% and
84.7+12.2%, respectively. EGF/TGF-a-LA, IR-TGF-a and
IR-EGF were not detected in any extract prepared from
fresh medium.
The levels of EGF/TGF-a-LA, IR-TGF-cx and IR-EGF in
the 41 spent media prepared from human tumour cell lines
were determined by the three assay systems and the results
were expressed as the concentrations (nmoll-1) equivalent to
the respective growth factors. As shown in Figure 2a, EGF/
TGF-a-LA was detected in 11 spent media. The dose-
response curves were parallel to that of hTGF-a(1-50). It is
worth noting that the frequency of TGF-a production and
its quantity in melanoma cell lines are high. As shown in
Figure 2b, the levels of IR-TGF-a were approximately equal
to those determined by RRA. In all of the 11 lines in which
EGF/TGF-a-LA was detected, IR-TGF-a was also detected.
Furthermore, a small amount of IR-TGF-a was detected in
an additional five lines. In the 11 cell lines producing both
EGF/TGF-cl-LA and IR-TGF-ax, the levels of EGF/TGF-a-
LA correlated well with those of IR-TGF-a (r=0.994,
P<0.005) (Figure 3). In contrast, no IR-EGF was detected
in the spent media.
Gelfiltration studies of TGF-a in melanoma cell lines
The gel filtration patterns of the extracts prepared from the
spent media of four melanoma cell lines are shown in Figure
4. Both hTGF-a RIA and RRA revealed a single peak at the
position corresponding to hTGF-a(1-50) in the three cell
lines. In the case of G-361, however, the major peak with
IR-TGF-oa was eluted at a position between hTGF-a(l-50)
and 125I-Na. RRA revealed that the major peak had the
ability to bind to the EGF receptor. When the extract
prepared from fresh medium was examined, no detectable
peak was observed.
Northern blot analysis in melanoma cell lines
Autoradiographs of Northern blot analysis using the probes
for hTGF-cc mRNA and P-actin mRNA are shown in Figure
5. Two bands were detected by the probe for hTGF-a
mRNA in the four melanoma cell lines which produced a
large amount of IR-TGF-ax. The molecular sizes of these
bands were 4.8 and 1.8kb, respectively. When the probe for
,B-actin mRNA was used, a 2.0 kb band was detected in each
cell line. The ratios of hTGF-a mRNA to ,B-actin mRNA
were calculated and are shown in Table II. The amount of
hTGF-a mRNA correlated well with the concentration of
IR-TGF-a in each cell line, when corrected by P-actin
mRNA (r=0.974, P<0.05).TGF-a PRODUCTION 763
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Figure 2 Frequency of detection and the quantities of factors
with capacity to bind to EGF receptor (EGF/TGF-a-LA)
determined by RRA (a) and IR-TGF-a determined by hTGF-a
RIA (b) in extracts prepared from the spent media of various
types of human tumour cell lines. Sq., squamous; ca., carcinoma.
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Figure 3 Correlation between levels of factors with capacity to
bind to EGF receptor (EGF/TGF-a-LA) determined by RRA
and those of IR-TGF-a determined by hTGF-a RIA in extracts
prepared from the spent media of 41 human tumour cell lines.
Discussion
In the present study, 11 out of 41 human tumour cell lines
(27%) were found to produce EGF/TGF-oa-LA when they
were examined by RRA using the membrane fraction of A-
431 cells. Simultaneous analysis of these 41 cell lines by
hTGF-ax RIA revealed that 16 (39%) of them secreted IR-
20 30 40 50 60
Fraction number
Figure 4 Gel filtration patterns of extracts prepared from the
spent media of melanoma cell lines measured by hTGF-a RIA
(0) and RRA (0). (a) SEKI; (b) A-375; (c) VMRC-MELG; (d)
G-361. The substances used for markers are shown at the top:
HA, 125I-human albumin; TGF-a, hTGF-c(I-50); 1251, 125I-Na.
TGF-ac. It is worth noting that all of the 11 lines producing
EGF/TGF-a-LA produced IR-TGF-a. In contrast, IR-EGF
was not detectable in any of these 41 cell lines. The facts
that the levels of EGF/TGF-a-LA correlated well with those
of IR-TGF-a and that the detection ability of hEGF RIA is
10 times better than that of hTGF-a RIA or RRA indicate
that EGF/TGF-a-LA detected in the spent media of these
human tumour cell lines is TGF-a rather than EGF.
TGF-a with a molecular size of 6kDa has been purified
from transformed rodent and human cells, sequenced and
cloned (Derynck et al., 1984; Lee et al., 1985a). On the other
hand, TGF-a-like activity of substances with different
molecular sizes has been detected in the spent media and
tumour cell extracts in several tumour cells (Bringman et al.,
1987; Teixido et al., 1987). We also have demonstrated that
TGF-a produced by human lung adenocarcinoma cell lines
has multiple molecular sizes; these were considered to be
macromolecular TGF-a, TGF-a(I-50) and molecules with
lower molecular sizes (Imanishi et al., 1988). In the present
study, we determined the molecular sizes of TGF-x produced
by melanoma cell lines, in which the frequency of TGF-cx
production and its quantity were high. Gel filtration studies
revealed that the molecular size of EGF/TGF-a-LA and IR-
TGF-a was identical to that of hTGF-at(l-50) in three of the
four melanoma cell lines examined. In the case of G-361,
however, the majir peak was eluted at a position behind
that of hTGF-a(I-50). The position of this peak eluted in
the present gel filtration suggests that this molecule is
different from those observed in the extracts prepared from
the spent media of human lung adenocarcinoma cell
--
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Figure 5 Detection of hTGF ca mRNA (A) and IJ actin mRNA
(B) in melanoma cell lines. (a) SEKI; (b) A-375; (c) VMRC-
MELG; (d) G-361; (e) WM 115; (f) WM-266-4; (g) Mewo. The
levels of EGF/TGF-a-LA and IR TGF-a in respective cell lines
are shown in Table * .
lines (Imanishi et al., 1988). Since both EGF/TGF' LA
and IR-TGF-a were detected in this peak, further
characterisation of this molecule may add information on
the structure biological activity relationship of the TGF-!.
molecule.
Northern blot analysis revealed that TGF-a produced by
the melanoma cell lines was actually the product of hTGF-cx
Table II Concentrations of EGF/TGF-a-LA and IR-TGF-a and
ratio of hTGF-a mRNA to fl-actin mRNA in melanoma cell lines
Melanoma EGF/TGF-a-LA IR-TGF-cx hTGF-a mRNA/
cell line (nmoll') (nmoll1- ) ,B-actin mRNAa
SEKI 2.4 3.2 100b
A-375 1.9 2.1 59
VMRC-MELG 0.15 0.18 10
G-361 0.15 0.19 27
WM-115 0.066 0.083 n.d.c
WM-266-4 <0.060 0.091 n.d.
Mewo <0.060 <0.052 n.d.
aThe amount of hTGF-oa mRNA was estimated as the ratio of the
hybrid band of hTGF-oc mRNA to that of /3-actin mRNA by
densitometric analysis; bThe hTGF-oa mRNA//3-actin mRNA ratio in
SEKI was taken as 100; cn.d. not detectable.
gene, according to the findings described below. Bands
corresponding to hTGF-a mRNA were detected in the four
melanoma cell lines producing a large amount of IR-TGF-oc.
The molecular sizes of these bands were almost the same as
those ofhTGF-a mRNA reported by Derynck et al. (1987) and
Coffey et al. (1987). Furthermore, the amount of hTGF-oa
mRNA correlated well with the concentration of IR-TGF-a
in each cell line. It is worth noting that the pattern of
hTGF-cx mRNA of G-361, in which TGF-a with different
molecular size was detected, was the same as that of the
other melanoma cell lines expressing hTGF-a mRNA.
The finding that the frequency of TGF-a production and
its quantity in melanoma cell lines are high suggests that
TGF-a plays an important role in these cells. There are
several reports of the production of TGF-oa by melanoma
cell lines (Marquardt et al., 1983; Derynck et al., 1987; Ellem
et al., 1988). Since TGF-a has been considered to be one of
the possible autocrine growth factors in cancer cells, several
studies were performed previously to clarify the role of
TGF-a as the autocrine growth factor for melanoma cells.
Singletary et al. (1987) reported that EGF enhanced the
growth of almost all melanoma cells prepared from surgical
specimens. Ellem et al. (1988) reported that in melanoma
cells and melanocytes the secretion of TGF-a was stimulated
by ultraviolet radiation and that TGF-a promoted their own
growth. In contrast, Kudlow et al. (1984) reported that a
monoclonal antibody against EGF receptor did not inhibit
the cellular growth of a melanoma cell line, suggesting that
TGF-oc could not function as an autocrine growth factor for
melanoma cells. As stated above, it is controversial at
present whether or not TGF-a is an autocrine growth factor
for melanoma cells. Further studies on this point should
clarify the actual roles of TGF-a in melanoma cells.
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